The White House has announced a significant price reduction for obesity drugs available through a new deal with Novo Nordisk and Eli Lilly, slashing costs from over $1,000 to approximately $350. This move is crucial as it makes essential medications more accessible to those struggling with obesity, potentially improving health outcomes for millions of Americans. By addressing the high costs of these treatments, the administration aims to alleviate financial burdens and promote healthier lifestyles.